Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-19 · Built: 2026-10-19 · 中文

← United States · Coverage record

US · SEC FORM 4

Metagenomi Therapeutics, Inc.

MGX · Nasdaq · CIK 0001785279 · Healthcare · Biotechnology

INSIDER SIGNAL

37.4 / 100

1 buyers · 2 purchase transaction lines · $23.4K gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeLow
RoleStrong
RecencyModerate
ConvictionLow
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+7.0 / 35
Purchase size+1.5 / 25
Role+20.0 / 20
Recency+5.1 / 10
Conviction+3.8 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
  • ⚠ Purchase size is modest relative to the model scale
  • ⚠ Buying conviction is reduced by concurrent selling
  • ✓ Role scores high · most senior buyer: Director

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Purchase breadth & concentration

QUALIFYING BUYERS1
PURCHASE CONCENTRATION100%Largest buyer: Reid Laurence · $23.4K
CLUSTER BUYING · 15D1 insiderPeak activity: 2026-09-09–2026-09-09

Roles in the peak window: Director. Concentration uses priced qualifying P lines only and does not change the saved score.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Wapnick PamelaChief Financial Officer
▼▼
Irish JianSee Remarks
▼▼
Wein MatthewSee Remarks
▼▼
Reid LaurenceDirector
●
● Purchase▼ Sale○ Other

—

SIGNAL HISTORY

37.4 / 100

Latest recorded score

↓ -0.1 ptsversus the previous recorded snapshot
  1. 37.9
  2. 37.8
  3. 37.7
  4. 37.5
  5. 37.4

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

2Purchases
13Sales
8Other Form 4 lines
20SEC filings · 365 days
BUYING2 qualifying P line(s) · 180 days
SELLING6 sale line(s) · context only
OTHER0 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-13.8%
3M
-24.2%
6M
-27.5%
12M
-68.7%

Volatility & liquidity

Volatility
115.2%
Beta
—
Avg daily value
USD 151,662

Valuation

Market cap
USD 37.8M
P/E
—

Fundamentals

Profit margin
-348.5%
ROE
-55.4%
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, Profit margin, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-08-06 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
1,271,863
Previous report
1,430,434
Avg daily volume
120,626
Days to cover
10.5

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-09Reid LaurencePurchase (P)Common Stock20,000USD 1.17USD 23,401SEC filing ↗
2024-02-13Novo Holdings A/SPurchase (P)COMMON STOCK800,000USD 15.00USD 12,000,000SEC filing ↗
2024-02-09Novo Holdings A/SPurchase (P)COMMON STOCK100,000USD 10.25USD 1,025,000SEC filing ↗

Form 4 evidence

23 transaction lines in the latest 365-day window; 59 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-09Reid LaurencePurchase (P)Common Stock20,000USD 1.17USD 23,401SEC filing ↗
2026-09-08Wein MatthewSale (S)Common Stock358USD 1.16USD 415SEC filing ↗
2026-09-08Wapnick PamelaSale (S)Common Stock1,911USD 1.16USD 2,217SEC filing ↗
Show recent Form 4 evidence (21 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-09Reid LaurencePurchase (P)Common Stock20,000USD 1.17USD 23,401SEC filing ↗
2026-09-08Wein MatthewSale (S)Common Stock358USD 1.16USD 415SEC filing ↗
2026-09-08Wapnick PamelaSale (S)Common Stock1,911USD 1.16USD 2,217SEC filing ↗
2026-09-08Irish JianSale (S)Common Stock2,140USD 1.16USD 2,482SEC filing ↗
2026-06-05Wein MatthewSale (S)Common Stock558USD 1.30USD 725SEC filing ↗
2026-06-05Wapnick PamelaSale (S)Common Stock2,884USD 1.30USD 3,749SEC filing ↗
2026-06-05Irish JianSale (S)Common Stock3,737USD 1.30USD 4,858SEC filing ↗
2026-04-01Wein MatthewAward / grant (A)Common Stock11,000USD 0.00USD 0SEC filing ↗
2026-04-01Wapnick PamelaAward / grant (A)Common Stock24,000USD 0.00USD 0SEC filing ↗
2026-04-01Irish JianAward / grant (A)Common Stock46,000USD 0.00USD 0SEC filing ↗
2026-03-05Wein MatthewSale (S)Common Stock482USD 1.60USD 771SEC filing ↗
2026-03-05Wapnick PamelaSale (S)Common Stock1,581USD 1.60USD 2,530SEC filing ↗
2026-03-05Irish JianSale (S)Common Stock1,607USD 1.60USD 2,571SEC filing ↗
2025-12-05Irish JianGift (G)Common Stock228,462USD 0.00USD 0SEC filing ↗
2025-12-05Wein MatthewSale (S)Common Stock199USD 1.77USD 352SEC filing ↗
2025-12-05Wapnick PamelaSale (S)Common Stock1,576USD 1.77USD 2,790SEC filing ↗
2025-12-05Thomas Brian C.Sale (S)Common Stock3,830USD 1.77USD 6,779SEC filing ↗
2025-12-05Irish JianSale (S)Common Stock1,602USD 1.77USD 2,836SEC filing ↗
2025-12-01Wein MatthewAward / grant (A)Common Stock96,000USD 1.60USD 153,600SEC filing ↗
2025-12-01Wapnick PamelaAward / grant (A)Common Stock120,000USD 1.60USD 192,000SEC filing ↗
2025-12-01Irish JianAward / grant (A)Common Stock248,500USD 1.60USD 397,600SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-19
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerMGX
CIK0001785279
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2836 Biological Products, (No Diagnostic Substances)
ExchangeNasdaq

Data coverage

Local Form 4 history59 transaction lines from 2024-02-09 to 2026-09-09
4 P purchase lines · 26 S sale lines · 29 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.